Read the full company presentation here.
And as I mentioned above, AWKNF has several potential catalysts to familiarize yourself with ASAP. Check them out:
No. 1 AWKNF Potential Catalyst - Volatile Situation? Check Out This Low Float
According to the OTC Markets' website, AWKNF has a low float.
The website reports this profile to have approximately 14.5Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could positive company news early in 2023 provide a near term spark?
No. 2 AWKNF Potential Catalyst - Could A Global Licensing Agreement For Phase I Data Be Nearing?
Awakn Life Sciences Initiates Investigative Study of Novel Formulation of (S)-ket-a-mine to Assess Dissociative Effect
Study Has Potential to Lead to In-Licensing Agreement and Accelerated Pathway to Phase II
Toronto, Ontario--(Newsfile Corp. - January 24, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has initiated an investigative study to establish the dissociative effect of a proprietary and patent pending formulation of (S)-ket-a-mine and optimized route of administration to support commercialization in due course.
Today's news builds on Awakn's announcement in August 2022 of a twelve-month option agreement with a leading drug development, manufacturing, and delivery systems company to in-license a proprietary formulation of (S)-ket-a-mine with an optimized route of administration.
The trial's participants will consist of harmful drinkers, they will be administered with a dose of (S)-ket-a-mine delivered via a proprietary oral thin film formulation. The study will evaluate the dissociative effect garnered from the formulation and look at alcohol cravings from participants. The study will also assess mechanistic factors including electroencephalographic (EEG) markers of increased neuroplasticity.
If the results of this study are positive, it will potentially lead to a global licensing agreement for phase I data of the patent pending oral thin film (S)-ket-a-mine formulation. This could result in Awakn advancing to a larger phase II b study and having global exclusivity rights to use the thin film formulation in the treatment of all addictions.
The mass adoption of intravenous delivered ket-a-mine-assisted therapy may be limited due to the requirement for specific infrastructure and clinicians to administer it. This emphasises the need for a novel route of administration.
Anthony Tennyson, Awakn CEO added, "This is an exciting development for Awakn which we believe will strengthen our innovative pipeline of therapeutics and corresponding IP. Critically it also has the potential to improve treatment options and experiences for so many people suffering from Alcohol Use Disorder, with so few effective options available to them, there has never been a greater need."
Read the full article here.
No. 3 AWKNF Potential Catalyst - Revenue Growth Continues To Pop-Off For AWKNF
Awakn Life Sciences Reports Strong Q3 2022 Results with 27% Revenue Growth
And continued successful execution of R&D and Commercialization strategies
Toronto, Ontario--(Newsfile Corp. - December 15, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today its financial results and business highlights for the three months ended October 31, 2022. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars ("CAD"), unless otherwise specified.
Anthony Tennyson, Chief Executive Officer of Awakn Life Sciences, stated, "Today's results and growth in revenue demonstrate continued progress in our business and successful execution of our business plan across both pillars of our business: R&D and Commercialization.
In R&D we initiated two feasibility studies to deepen Awakn's IP moats and potentially improve patient experience and outcomes. The first study, with Catalent, a global leader in delivery technologies and drug manufacturing, investigates a market-ready proprietary formulation of MDMA using Catalent's Zydis® technology. The second study, with a leading European pharmaceutical company, investigates a market-ready proprietary formulation of Esket-a-mine. If successful either or both feasibility studies could lead to exclusive licensing agreements. Post quarter close, on 13th December, we also announced that Phase III of our lead program, Project Kestrel, will be delivered in the U.K.'s public healthcare system, the NHS, and confirmed the total cost of the trial will be CA$3.75m with the U.K. government agencies providing grant funding for 66% of this cost.
In Commercialization, our clinics delivered continued strong revenue growth of 27% QoQ and we launched our licensing partnership business into the US and Canada, signing three partners in Q3, providing Awakn with two distinct revenue streams across four territories. Post quarter close, in November and December, we announced the expansion of our clinic footprint in Norway on the back of strong demand for our services in that territory."
2Q22 & Recent Financial Highlights:
Delivered revenue of $430,504 via Awakn's clinics for the three months ended October 31, 2022, compared to $Nil in the prior year. This represents a 27% or $90,673 increase versus the three months ended July 31, 2022.
Revenue during the period was primarily driven by the provision of ket-a-mine-assisted therapies at the London, Bristol and Oslo Awakn clinics.
Read the full article here.
No. 4 AWKNF Potential Catalyst - A Potential Bounce/Reversal Could Be Nearing Following A Recent Downtrend
As of close Friday, Barchart was reporting this profile to have multiple oversold leaning technicals.
These technicals could be signaling a healthy reversal could be approaching in the near term.
Here's the definition of a "reversal" from Investopedia:
"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."
Now, here are some key technicals (as of close Friday) that could signal AWKNF to be leaning oversold and on the verge of a potential reversal.
- 14-Day Raw Stochastic: 19.40%
- 14-Day Williams %R: 80.60%
As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued.
Keep an eye on these technicals closely.
AWKNF Recap - Multiple Potential Breakout Catalysts To Know
No. 1 - Volatile Situation? Check Out This Low Float
No. 2 - Could A Global Licensing Agreement For Phase I Data Be Nearing?
No. 3 - Revenue Growth Continues To Pop-Off For AWKNF
No. 4 - A Potential Bounce/Reversal Could Be Nearing Following A Recent Downtrend
Coverage is officially initiated on AWKNF. When time permits, do this: